Yahoo · Nov 11, 2026
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
First revenue lands as the ARDS trial enters randomized Phase II.
IN
NASDAQ · INKT
MiNK Therapeutics, Inc.
Healthcare · Biotechnology
$9.53
Down-$0.43 (-4.49%)
Updated Nov 13, 2026, 4:15 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 58.3M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $8.48 – $16.93
- Volume
- 14.71K
- Avg. volume
- 28.08K
Price performance · INKT
INKT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
INKT closed at $9.53 after 21 trading sessions, down 4.12% for the selected period.
- Last close
- $9.53
- Period change
- -4.12%
- Period low
- $9.41
- Period high
- $11.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $10.20 | $10.375 | $9.53 | $9.53 | 14.71K |
| Nov 11, 2026 | $10.51 | $10.88 | $10.0201 | $10.2239 | 14.91K |
| Nov 10, 2026 | $10.06 | $10.50 | $10.00 | $10.01 | 4.53K |
| Nov 9, 2026 | $10.35 | $10.99 | $10.25 | $10.295 | 9.84K |
| Nov 6, 2026 | $9.82 | $10.88 | $9.82 | $10.35 | 7.67K |
| Nov 5, 2026 | $10.59 | $10.59 | $9.6088 | $10.05 | 15.69K |
| Nov 4, 2026 | $11.03 | $11.03 | $10.6001 | $10.6001 | 6.07K |
| Nov 3, 2026 | $10.88 | $11.265 | $10.70 | $10.79 | 8.44K |
| Nov 2, 2026 | $10.41 | $11.48 | $10.41 | $11.04 | 11.61K |
| Oct 30, 2026 | $10.55 | $10.86 | $10.3501 | $10.53 | 8.68K |
| Oct 29, 2026 | $10.83 | $11.13 | $10.4051 | $10.875 | 9.69K |
| Oct 28, 2026 | $10.76 | $11.4499 | $10.76 | $10.80 | 6.13K |
| Oct 27, 2026 | $10.48 | $10.8466 | $10.4079 | $10.63 | 10.15K |
| Oct 26, 2026 | $10.75 | $11.40 | $10.43 | $10.43 | 13.32K |
| Oct 23, 2026 | $10.635 | $11.68 | $10.18 | $10.71 | 29.54K |
| Oct 22, 2026 | $10.65 | $10.65 | $10.06 | $10.06 | 9.83K |
| Oct 21, 2026 | $9.80 | $10.99 | $9.80 | $10.62 | 18.61K |
| Oct 20, 2026 | $9.31 | $9.97 | $9.19 | $9.86 | 8.44K |
| Oct 19, 2026 | $9.61 | $9.68 | $9.25 | $9.56 | 14.15K |
| Oct 16, 2026 | $9.87 | $10.10 | $9.38 | $9.41 | 13.63K |
| Oct 15, 2026 | $10.35 | $10.35 | $9.9337 | $9.94 | 10.1K |
Latest INKT news
The latest Smart Investors Daily articles mentioning INKT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INKT research
Overview
Company profile and research snapshot.
Company profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | B. Riley Securities | Buy | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 11, 2026
MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of MiNK Therapeutics, Inc.'s Q3 2026 earnings call
Yahoo · Nov 11, 2026
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
MiNK Therapeutics Inc (INKT) pairs durable oncology survival data with a newly initiated randomized ARDS program, all while maintaining a disciplined cash runway of at least 12 months.
Yahoo · Nov 11, 2026
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with preliminary findings expected in the second half of 2026, executives said on the company’s first-quarter ear
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
